Cancer immunotherapy has been regarded as the most significant scientific breakthrough of 2013, and antibody therapy is at the core of this breakthrough. Despite significant success achieved in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies comprise a novel family of antibodies that can recognize peptide/MHC complexes on tumor cell surfaces. TCR-like antibodies can execute specific and significant anti-tumor immunity through several distinct molecular mechanisms, and the success of this type of antibody therapy in melanoma, leukemia, and breast, colon, and prostate tumor models has excited researchers in the immunotherapy field. Here, we summarize the generation strategy, function, and molecular mechanisms of TCR-like antibodies described in publications, focusing on the most significant discoveries.

中文翻译：

---

TCR样抗体在癌症免疫治疗中。

癌症免疫疗法被视为2013年最重大的科学突破，抗体疗法是这一突破的核心。尽管近年来取得了巨大的成功，但是仍然难以用传统抗体靶向肿瘤细胞的细胞内抗原，并且需要新颖的治疗策略。T细胞受体（TCR）样抗体包含可以识别肿瘤细胞表面上的肽/ MHC复合物的新型抗体家族。类似于TCR的抗体可以通过几种不同的分子机制执行特异性和重要的抗肿瘤免疫，这种类型的抗体疗法在黑素瘤，白血病以及乳腺癌，结肠癌和前列腺癌模型中的成功获得了免疫治疗领域的研究人员的欢迎。在这里，我们总结了生成策略，功能，